Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1366 results about "Signal peptide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A signal peptide (sometimes referred to as signal sequence, targeting signal, localization signal, localization sequence, transit peptide, leader sequence or leader peptide) is a short peptide (usually 16-30 amino acids long) present at the N-terminus of the majority of newly synthesized proteins that are destined towards the secretory pathway. These proteins include those that reside either inside certain organelles (the endoplasmic reticulum, Golgi or endosomes), secreted from the cell, or inserted into most cellular membranes. Although most type I membrane-bound proteins have signal peptides, the majority of type II and multi-spanning membrane-bound proteins are targeted to the secretory pathway by their first transmembrane domain, which biochemically resembles a signal sequence except that it is not cleaved. They are a kind of target peptide.
Expression and secretion of heterologous proteins in yeast employing truncated alpha-factor leader sequences
InactiveUSRE37343E1Efficiently direct expressionEfficient secretionPolypeptide with localisation/targeting motifFungiHeterologousBiotechnology
A yeast alpha-factor expression system is provided comprised of a truncated leader sequence, containing the alpha-factor signal peptide and one glycosylation site, linked by a processing site to a non-yeast protein-encoding sequence.
Owner:CHIRON CORP
Direct expression of peptides into culture media
InactiveUS6103495AReduced viabilityImprove breathabilityBacteriaPeptide/protein ingredientsGrowth phaseBiotechnology
Expression systems are disclosed for the direct expression of peptide products into the culture media where genetically engineered host cells are grown. High yield was achieved with novel vectors, a special selection of hosts, and / or fermentation processes which include careful control of cell growth rate, and use of an inducer during growth phase. Special vectors are provided which include control regions having multiple promoters linked operably with coding regions encoding a signal peptide upstream from a coding region encoding the peptide of interest. Multiple transcription cassettes are also used to increase yield. The production of amidated peptides using the expression systems is also disclosed.
Owner:ENTERIS BIOPHARMA
Secretion signal vectors
InactiveUS7071172B2Minimize potential deleterious side effectAttenuate seizure activityBiocideAnimal repellantsHeterologousAdeno associate virus
The present invention provides delivery vectors for transferring a nucleic acid sequence to a cell in vitro, ex vivo or in vivo. The delivery vector comprises a segment encoding a secretory signal peptide. In embodiments of the invention, the delivery vector is an adeno-associated virus (AAV) vector. In other embodiments, the secretory signal peptide is a fibronectin secretory signal peptide (including variations and modifications, thereof). The delivery vectors of the invention may further comprise a heterologous nucleic acid sequence encoding a polypeptide of interest for transfer to a target cell, where the polypeptide of interest is operably associated with the secretory signal. Also disclosed are methods of transferring a nucleic acid of interest to a cell using the delivery vectors of the invention.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
Bacterial leader sequences for increased expression
ActiveUS20080193974A1Promote targetingSimple compositionPolypeptide with localisation/targeting motifSugar derivativesNucleotideADAMTS Proteins
Compositions and methods for improving expression and / or secretion of protein or polypeptide of interest in a host cell are provided. Compositions comprising a coding sequence for a bacterial secretion signal peptide are provided. The coding sequences can be used in vector constructs or expression systems for transformation and expression of a protein or polypeptide of interest in a host cell. The compositions of the invention are useful for increasing accumulation of properly processed proteins in the periplasmic space of a host cell, or for increasing secretion of properly processed proteins from the host cell. In particular, isolated secretion signal peptide-encoding nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the nucleic acid molecules are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequences shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24, and the nucleotide sequences set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23, as well as variants and fragments thereof.
Owner:PFENEX
Bacterial leader sequences for increased expression
ActiveUS7618799B2Reduce environmental pollutionHigh expressionBacteriaAntibody mimetics/scaffoldsADAMTS ProteinsAmino acid
Owner:PELICAN TECH HLDG INC
Diagnostics based on signal peptide detection
The invention provides methods and a kit for detecting peptides and proteins, which may be indicative of heart disease by detecting signal peptide levels for a protein in a subject's bodily fluid.
Owner:INVERNESS MEDICAL SWITZERLAND GMBH
Protein expression vector and utilization thereof
InactiveUS7029909B1Improve purification effectPolypeptide with localisation/targeting motifAnimal cellsProtein targetNucleotide
A protein expression vector containing (a) a nucleotide sequence encoding an IgG(κ) or a trypsin secretory signal peptide, (b) a nucleotide sequence encoding a polyhistidine amino acid sequence, (c) a nucleotide sequence encoding an amino acid sequence comprising amino acid residues 36–40 of SEQ ID NO:19 (Asp-Asp-Asp-Asp-Lys), which is cleavable by an enterokinase, and (d) a cloning site into which a nucleotide sequence encoding a target protein can be inserted, wherein (a), (b), (c) and (d) are assembled within the vector in the order recited.
Owner:FUSO PHARMA INDS
Novel chimeric antigen receptor and applications thereof
PendingCN108276493AMild release responseHigh ability to target and recognize tumor antigensPolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorsAntigen binding
The present invention discloses a novel chimeric antigen receptor and applications thereof, wherein the novel chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a transmembrane domain and an intracellular signal domain, and comprises a 4-1BB signal peptide and / or a 4-1BB molecular transmembrane domain. According to the present invention, a variety of chimeric antigenreceptor nucleic acid sequences are separated and purified, the chimeric antigen receptor specifically for CD19 malignant tumor antigens and the CAR-T cells are provided, and the blood cell line malignant tumor killing test results show that the tumor-cell-targeting ability of immune cells is significantly enhanced, and the tumor cell killing activity is enhanced.
Owner:NANJING LEGEND BIOTECH CO LTD
Production of recombinant human serum albumin with rice-embryo milk cell as biological reactor
ActiveCN1896239ANo pollution in the processEfficient expressionSerum albuminFermentationSerum protein albuminEmbryo
Production of recombinant human serum albumin with rice albuminous cell as biological reactor is carried out by taking rice albuminous cell protein as storage site for recombinant protein, taking rice albuminous specific expression starter and signal peptide, entering inductive recombinant human serum albumin into inner-film system of rice serum albumin cell and storing it in rice albuminous protein. It is cheap, has more yield and higher expression.
Owner:WUHAN HEALTHGEN BIOTECHNOLOGY CORP
Method for producing recombinant proteins in micro-organisms
The invention relates to a method for producing a recombinant functional plasminogen in micro-organisms, and to a method for identifying plasminogen activators. The nucleic acid sequence coding for the functional part of the plasminogen is fused with a nucleic acid molecule coding for at least one signal peptide. The nucleic acid molecule coding for the plasminogen and the nucleic acid molecule coding for the signal peptide are combined with codons for interfaces of proteases which ensure the separation of the signal peptide. The recombinant plasminogen or the corresponding plasmine is suitable for treating wounds which are slow to heal or not healing, by application of the enzyme in an appropriate formulation.
Owner:N-酶生物技术有限公司
Secretion of antibodies without signal peptides from bacteria
The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries.
Owner:KALOBIOS PHARMA
Process for the fermentative production of proteins
InactiveUS20080254511A1High-yieldPolypeptide with localisation/targeting motifBacteriaBiotechnologyHeterologous
The present invention relates to a process for producing a heterologous protein by means of an E. coli strain in a fermentation medium. The process comprises fermenting an E. coli strain in a fermentation medium. The E. coli strain has a mutation in the lpp gene or in the promoter region of the lpp gene, and contains a gene coding for a heterologous protein which is functionally linked to a signal sequence coding for a signal peptide. The fermentation medium includes Ca2+ ions in a concentration above 4 mg / l or Mg2+ ions in a concentration above 48 mg / l. The E. coli strain secretes the heterologous protein into the fermentation medium. The protein is removed from the fermentation medium.
Owner:WACKER CHEM GMBH
Anti-BCMA chimeric antigen receptor, encoding gene, recombinant expression vector and establishing method and application of anti-BCMA chimeric antigen receptor, encoding gene and recombinant expression vector
ActiveCN105777911AImprove in vitro killing effectGood clinical effectPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsSequence signalSingle-Chain Antibodies
The invention discloses an anti-BCMA chimeric antigen receptor, an encoding gene, a recombinant expression vector and an establishing method and application of the anti-BCMA chimeric antigen receptor, the encoding gene and the recombinant expression vector. The receptor comprises a CD8 leader chimeric receptor signal peptide, a BCMA single-chain antibody heavy chain VH, an Optimal Linker C, a BCMA single-chain antibody light chain VL, a CD8 Hinge chimeric receptor hinge, a CD8 Transmembrane chimeric receptor transmembrane domain, a CD137 chimeric receptor co-stimulatory factor and a TCR chimeric receptor T cell activating domain which are sequentially connected in series. In addition, the invention further discloses the encoding gene and the recombinant expression vector of the anti-BCMA chimeric antigen receptor and the establishing method and application of the encoding gene and the recombinant expression vector. The secretion of cell factors and the cytotoxicity in vitro of CAR-T cells can be remarkably improved, and the clinical treatment effect is outstanding.
Owner:SHANGHAI UNICAR THERAPY BIOPHARM TECH CO LTD
Variant polypeptides and methods of making
InactiveUS20080070287A1High hydrolytic activityIncreased activity transferase activityBacteriaHydrolasesBacillus licheniformisLipid formation
The present invention relates to a method for the production of a variant lipid acyltransferase comprising the steps of: (i) selecting a parent enzyme which is a lipid acyltranserase enzyme; (ii) modifying one or more amino acids to produce a variant lipid acyltransferase; (iii) testing the activity of the variant lipid acyltransferase on a galactolipid and / or phospholipid and / or triglyceride substrate; (iv) selecting a variant enzyme with enhanced activity towards galactolipids compared with the parent enzyme; (v) providing a Bacillus licheniformis cell; (vi) transforming the Bacillus licheniformis cell with a heterologous nucleotide sequence encoding said variant lipid acyltransferase; and (iii) expressing said variant lipid acyltransferase in the cell under the control of a promoter sequence. The variant lipid acyltransferase can undergo post-translations modification, truncation and / or clipping, i.e., to remove a signal peptide. In addition, the present invention further relates to the use of Bacillus licheniformis to express a lipid acyltransferase, a Bacillus licheniformis host cell comprising a heterologous lipid acyltransferase and a vector comprising a nucleotide sequence encoding a lipid acyltransferase operably linked to a promoter sequence homologous to B. licheniformis.
Owner:DUPONT NUTRITION BIOSCIENCES APS
Complementary DNAs encoding proteins with signal peptides
InactiveUS7385034B2Improve purification effectSugar derivativesPeptide/protein ingredientsADAMTS ProteinsSecretory protein
The sequences of cDNAs encoding secreted proteins are disclosed. The cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design expression vectors and secretion vectors.
Owner:SERONO GENETICS INST SA
In vivo gene therapy of parkinson's disease
InactiveUS20060239966A1Good treatment effectEasy treatmentBiocideNervous disorderIn vivoMammalian cell
The present invention concerns methods and compositions for gene therapy, in particular in vivo gene therapy for delivery of bioactive Neurturin for the treatment of Parkinson's Disease. In another aspect the invention relates to virus expression constructs comprising a mammalian signal peptide linked to a mature or N-terminally truncated Neurturin without a functional pro-region between the signal peptide and the Neurturin. These viral expression constructs are required for efficient secretion of bioactive Neurturin in in vivo gene therapy. The invention also concerns mammalian cells capable of producing Neurturin in increased amounts as well as the use of these cells for recombinant production of bioactive Neurturin and for therapeutic use.
Owner:CEREGENE
Direct expression of peptides into culture media
InactiveUS6210925B1Reduced viabilityImprove breathabilityBacteriaPeptide/protein ingredientsGrowth phaseBiotechnology
Owner:ENTERIS BIOPHARMA
Method of protein production in plants
InactiveUS20050015830A1Increase flexibilityHigh expressionDepsipeptidesPeptide preparation methodsBiotechnologyNucleotide
A process of producing a protein or polypeptide of interest in a plant or in plant is provided, comprising: (i) transforming or transfecting a plant of plant cells with a nucleotide sequence having a coding region encoding a fusion protein comprising the protein or polypeptide of interest, a signal peptide functional for targeting said fusion protein to the apoplast, and a polypeptide capable of binding the fusion protein to a cell wall component, (ii) enriching cell wall components having expressed and bound fusion protein, and separating the protein or polypeptide of interest or a protein comprising the protein or polypeptide interest.
Owner:ICON GENETICS
Porcine circovirus type 2 subunit vaccine and preparation method thereof
InactiveCN101884787AImprove biological activityHighly species-specificViral antigen ingredientsVirus peptidesOpen reading frameAntigenicity
The invention mainly aims to provide a porcine circovirus type 2 (PCV2) subunit vaccine and a preparation method thereof. Particularly, a baculovirus vector expression system is utilized to express a large amount of recombinant open reading frame type 2 (ORF2) protein in insect cells, so that the subunit vaccine with good immunity effect is developed. A bac-to-bac baculovirus expression system is adopted to perform whole gene amplification on the porcine circovirus type 2 ORF2 gene, and a melittin signal peptide nucleotide sequence is introduced into a terminal 5', so that the recombinant baculovirus of an open reading frame containing the melittin signal peptide nucleotide sequence and a PVC2ORF2 gene sequence is established, wherein the infected insect cell expresses the recombinant ORF2 protein with efficient and high PCV2 antigenicity; and thus the subunit vaccine containing the PCV2 recombinant ORF2 protein is prepared. The inoculation experiments of piglets show that the subunit vaccine has a good immunity protection effect.
Owner:PU LIKE BIO ENG
Method for identification of cDNAs encoding signal peptides
InactiveUS20020127557A1Fast wayBacteriaMicrobiological testing/measurementScreening techniquesPresent method
The present invention provides a method in which cDNAs that encode signal sequences for secreted or membrane-associated proteins are isolated using a fusion protein that directs secretion of a molecule that provides antibiotic resistance, e.g., .beta.-lactamase. The present method allows the isolation of signal peptide-associated proteins that may be difficult to isolate with other techniques. Moreover, the present method is amenable to throughput screening techniques and automation, and especially in validating the presence of the signal sequence via expression of the protein in both prokaryotic and eukaryotic cells. This invention provides a powerful and approach to the large scale isolation of novel secreted proteins.
Owner:INCYTE CORP
Antigen specific multi epitope vaccines
ActiveUS20100074925A1Strong and comprehensive responseEffective immune responseTumor rejection antigen precursorsSugar derivativesMHC class IProtein target
The present invention relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The peptide vaccines of the invention are characterized by having multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines are likely to induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the invention relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.
Owner:VAXIL BIOTHERAPEUTICS
Fermentation method for production of heterologous gene products in lactic acid bacteria
or continuous process for producing heterologous peptides, polypeptides or proteins in lactic acid bacteria, comprising the steps of (i) constructing a recombinant lactic acid bacterium comprising a nucleotide sequence coding for the heterologous peptide, polypeptide or protein, and appropriate regulatory nucleotide sequences such as regulatable promoters and signal peptides to control the expression of the coding sequence and the secretion of gene product, (ii) cultivating the recombinant bacterium under or continuous cultivation conditions to express the gene, and (iii) harvesting the recombinant bacterium or the gene product. Preferably, the cultivation medium is a chemically defined or synthetic medium optionally supplemented with yeast extract.
Owner:BIONEER
Leader sequences for use in production of proteins
InactiveUS20070141666A1Efficient secretionEasy to handlePolypeptide with localisation/targeting motifSugar derivativesDNA constructTissues types
This invention encompasses novel leader sequences for production of proteins. More specifically, the invention relates to DNA constructs encoding leader sequences comprising an immunoglobulin signal peptide fused to a tissue-type plasminogen activator propeptide, and to DNA constructs encoding leader sequences comprising a truncated human tissue-type plasminogen activator propeptide. The invention further relates to the use of these DNA constructs for producing proteins in mammalian cells.
Owner:MERCK SERONO SA
Recombinant bacillus subtilis and method for producing transglutaminase by utilizing recombinant bacillus substilis
InactiveCN102586167AReduce breakageSimplify the fermentation production processBacteriaTransferasesStreptoverticillium mobaraenseGlutaminase
The invention discloses a recombinant bacillus subtilis and a method for producing transglutaminase by utilizing the recombinant bacillus substilis. The recombinant bacillus subtilis is obtained by the following steps of: (1) by virtue of fusion PCR (polymerase chain reaction), connecting a P43 promoter and a signal peptide gene with a subtilisin-like protease gene, and converting a fusion PCR amplification product into bacillus subtilis WB800 to obtain bacillus subtilis B.subtilis WB800S; and (2) carrying out PCR amplification on streptoverticillium mobaraense transglutaminase protogene, andthen converting amplification product into the bacillus subtilis B.subtilis WB800S to obtain bacillus subtilis B.subtilis WB800S / proMTG. The bacillus subtilis B.subtilis WB800S / proMTG is fermented and purified to obtain soluble transglutaminase. By adopting the method disclosed by the invention, the transglutaminase with biological activity can be directly obtained in supernatant of fermentation liquor, fussy processes of breaking cells and activating proenzyme after purification are eliminated, and a fermentation production process is simplified.
Owner:SOUTH CHINA UNIV OF TECH +1
Nucleic acid respiratory syncytial virus vaccines
InactiveUS6083925AGood immune protectionImprove expression levelSsRNA viruses negative-senseGenetic material ingredientsHeterologousF protein
Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.
Owner:CONNAUGHT LAB
Dual chain synthetic heparin-binding growth factor analogs
InactiveUS20050222394A1Ameliorate harmful effect of radiationOrganic active ingredientsPeptide/protein ingredientsBackbone chainBinding domain
The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.
Owner:BROOKHAVEN SCI ASSOCS
Heterologous Biomass Degrading Enzyme Expression in Thermoanaerobacterium Saccharolyticum
InactiveUS20120040409A1Increased chaperone activityDecrease protease activityBacteriaSugar derivativesThermoanaerobacterium saccharolyticumNucleotide
Thermophilic gram-positive anaerobic host cells, for example Thermoanaerobacterium saccharolyticum (“T sacch”), express heterologous biomass degrading enzymes, such as cellulases, and are able to produce useful fermentation products from cellulose. Useful fermentation products include, for example, ethanol, acetic acid, lactic acid or CO2. In order to provide maximum expression and activity levels, biomass degrading enzymes can be expressed from codon-optimized nucleotide sequences, can be expressed under the control of a high-efficiency promoter, and / or can be fused to a signal peptide. In addition, the host cell, for example, a T sacch host cell, can be genetically altered to further improve ethanol production, for example by disrupting the production of organic products other than ethanol.
Owner:ENCHI
Methods for secretory production of proteins
The object of the present invention is to provide a method of producing a heterologous protein by making a coryneform bacterium to produce and efficiently extracellularly secrete (secreto-production) an industrially useful heterologous protein. According to the present invention, a genetic construct is used where a gene sequence encoding an intended protein which is ligated to the downstream of a sequence encoding the signal peptide derived from a coryneform bacterium, the gene construct is introduced into a mutant coryneform bacterium which has a capacity of secreting the heterologous protein at least 2-fold higher than the wild type Corynebacterium glutamicum ATCC 13869, the mutant coryneform bacterium is cultured and the extracellularly released heterologous protein is recovered.
Owner:AJINOMOTO CO INC
Chimeric antigen receptors with an optimized hinge region
Owner:CHEMOTHERAPEUTISCHES FORSCHUNGINSTITUT GEORG SPEYER HAUS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com